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Abstract  29 
To characterize the risk of cosmetic ingredients when threshold toxicity is assumed, often the 30 
“margin of safety” (MoS) is calculated. This uncertainty factor is based on the systemic no observable 31 
(adverse) effect level (NO(A)EL) which can be derived from in vivo repeated dose toxicity studies. As 32 
in vivo studies for the purpose of the cosmetic legislation are no longer allowed in Europe and a 33 
validated in vitro alternative is not yet available, it is no longer possible to derive a NO(A)EL value for 34 
a new cosmetic ingredient. Alternatively, cosmetic ingredients with a low dermal bioavailability 35 
might not need repeated dose data, as internal exposure will be minimal and systemic toxicity might 36 
not be an issue. This study shows the possibility of identifying compounds suspected to have a low 37 
dermal bioavailability based on their physicochemical properties (molecular weight, melting point, 38 
topological polar surface area and log P) and their in vitro dermal absorption data. Although 39 
performed on a limited number of compounds, the study suggests a strategic opportunity to support 40 
the safety assessor’s reasoning to omit a MoS calculation and to focus more on local toxicity and 41 
mutagenicity/genotoxicity for ingredients for which limited systemic exposure is to be expected. 42 
  43 
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Introduction  44 
According to the European Cosmetic Regulation (EC 1223/2009), every cosmetic product on the 45 
market has to be safe for human health. This safety is based on the safety of its composing 46 
ingredients, their chemical structure, toxicological profile and exposure pattern. To characterize the 47 
risk of a cosmetic ingredient when threshold toxicity is assumed, the calculation of a so-called 48 
“margin of safety” (MoS) is applied. This uncertainty factor is used to extrapolate from test animals 49 
to humans and takes into account the systemic no observable (adverse) effect level (NO(A)EL) and 50 
the systemic exposure dose (SED). The former is derived either from in vivo oral repeated dose 51 
toxicity studies or reproductive toxicity data. The SED is estimated by taking into account the 52 
concentration (C) of the ingredient in the product, the daily amount of product exposed to per kg 53 
body weight (A, derived from consumer studies) and the dermal absorption (DA) [ MoS= 
NOAELsys
SED
 ;  54 
SED (mg/kg bw/day) = A(mg/kg bw/day) x C(%)/100 x DA(%)/100]. As proposed by the World Health 55 
Organisation (WHO) an ingredient with a MoS ≥ 100 is considered to be safe (SCCS/1564/15). 56 
However, with the introduction of the animal testing and marketing bans in the European cosmetic 57 
legislation and due to the absence of validated in vitro replacement methods for repeated dose or 58 
reproductive toxicity studies, it is no longer possible to derive a NO(A)EL to calculate the MoS for 59 
newly developed cosmetic ingredients. The consequences of this legal implementation start to 60 
become visible as no new UV-filters, preservatives or other cosmetic active ingredients have 61 
emerged in the last 2 years. So far only substances for which in vivo repeated dose studies were 62 
carried out before March 2013 have been evaluated by the SCCS. But for some particular ingredients 63 
the safety assessment might not be jeopardised. Indeed, ingredients with a negligible dermal 64 
bioavailability do not necessarily need repeated dose data, as internal exposure would be minimal 65 
and systemic toxicity might not be a potential issue. Adding the assumption that the main route of 66 
exposure to a cosmetic product is dermal and the dermal bioavailability will be in most cases even 67 
lower than the oral bioavailability, it might be justifiable to base the safety assessment of such 68 
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compounds on local toxicity and mutagenicity/genotoxicity test results, this on the assumption that 69 
no bioaccumulation is expected. In this context it is important to define when an ingredient is 70 
considered to have a low bioavailability. 71 
Bioavailability, defined as the fraction of the dose administered (orally, dermally or via another 72 
route) that reaches the systemic circulation unchanged, is a composite parameter dependent on 73 
both absorption from the site of administration and metabolism of the compound. Within the area of 74 
drug discovery much research has been carried out on predicting bioavailability, particularly with 75 
respect to oral administration.  As absorption is a key component, simple rules have been established 76 
that can be used to indicate the likelihood of absorption from the gastro-intestinal tract; the most 77 
well-known of these being the Lipinski rules (Lipinski et al., 2001). Briefly, the Lipinski “rule of fives” 78 
states that a logarithm of the octanol:water partition coefficient (log P) >5; molecular weight (MW) > 79 
500; number of hydrogen bond acceptors >10; and number of hydrogen bond donors > 5 are 80 
features associated with poor oral absorption. Veber et al (2002) showed that compounds with high 81 
topological polar surface area (TPSA) and a high number of rotatable bonds are also associated with 82 
poor oral absorption. Furthermore a relationship has been shown between oral absorption and 83 
melting point (MP): chemicals with a higher MP are less likely to be absorbed (Chu et al. 2009). The 84 
“General Solubility Equation” relates melting point to solubility and partition coefficient. The 85 
advantage of using MP is that it is more easily determined than oral absorption. Additionally, Newby 86 
et al. (2015) have recently published decision trees to characterise the roles of certain 87 
physicochemical properties on the prediction of oral absorption. Whilst these rules are broad, and 88 
many exceptions are known, they demonstrate the principle that these simple physicochemical 89 
descriptors may be useful in classifying compounds as to high or low (oral) absorption.  90 
Similarly, models have been developed to predict the extent of dermal penetration based on simple 91 
physicochemical properties; the most notable example being the work of Potts and Guy (1992) who 92 
demonstrated a correlation between log P and MW with skin permeability. Refinements to the Potts 93 
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and Guy model have since been published and the inherent difficulty modelling skin permeability 94 
data has been acknowledged (Steinmetz et al 2015). One problem is that measurements of dermal 95 
uptake are associated with high experimental variability, due to differences in assay conditions (e.g. 96 
differences in test protocols, skin type, use of solvents/vehicles, etc) making the development of 97 
robust, reliable quantitative models challenging. Another complication in modelling absorption is 98 
bias within the datasets. As skin is an effective barrier, dermal absorption data tend to be highly 99 
skewed towards low dermal absorption. The converse is observed for oral absorption data, as most is 100 
derived from drug development where high oral absorption is desirable, consequently most 101 
publically available data are for high oral absorption compounds. Despite these challenges, it would 102 
clearly be beneficial if rules based on simple physicochemical descriptors could be used to identify, 103 
accurately, compounds with low dermal absorption and thus low dermal bioavailability. 104 
In order to investigate this possibility, a retrospective analysis of available safety evaluation data of 105 
cosmetic ingredients could provide valuable information. Although the safety of cosmetic products 106 
and their ingredients in Europe has to be assured by the companies’ responsible person, for 107 
ingredients with some concern for human health i.e. colorants, preservatives, UV-filters and hair dyes 108 
(i.e. Annex substances), industry has to submit a full toxicological dossier to Directorate-General (DG) 109 
Sante when a mandate has been issued by DG Grow (Directorate-General for Internal Market, 110 
Industry, Entrepreneurship and SMEs of the EU). Risk assessment is than carried out according to the 111 
SCCS’ Notes of Guidance (SCCS/1564/15). The resulting risk assessments, known as “opinions”, are 112 
publically available via:  113 
http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm. These contain 114 
summaries of the studies on the different toxicological endpoints as well as the physicochemical 115 
characteristics and DA of the ingredient under investigation. Data collated from these opinions can 116 
provide a high quality dataset for analysis. To formulate rules to identify low bioavailability 117 
compounds we undertook an empirical analysis of the cosmetic ingredients, assessed between 2000 118 
and 2014 by the SCCS and its predecessors, to investigate the link between DA measured in vitro and 119 
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their physicochemical properties. In this study we propose a pragmatic approach that might aid in 120 
assessing whether a new cosmetic ingredient is likely to have a low dermal bioavailability.  121 
Method 122 
When preparing the data of all compounds from the SCCS opinions for modelling, the following 123 
criteria were used: 124 
(i) DA measurements obtained using rat skin were excluded because of the relatively high uptake 125 
when compared to human or porcine skin.  126 
(ii) if more than one DA measurement per compound were available an arithmetic mean was 127 
calculated. 128 
(iii) descriptors were obtained for the parent form of the compounds.   129 
A simplified molecular-input line-entry specification (SMILES) string for each compound was entered 130 
into the Molecular Operating Environment (MOE) software (version 2011.10) and processed to 131 
derive the neutralised form for the organic component. Topological polar surface area (TPSA) and 132 
molecular weight (MW) were calculated using a Chemistry Development Kit (CDK) node (molecular 133 
properties) available via the Konstanz Information Miner (KNIME) platform (KNIME version 2.10). The 134 
octanol:water partition coefficient (log P) was calculated using KowWin® (v1.68 available within EPI 135 
Suite 4.1, US EPA). Melting points (MPs) were extracted from the SCCS reports where possible. As the 136 
MPs of salts differ significantly from the MP of the parent compound, data was only included if 137 
available for the parent and not a salt form. This led to the creation of the data set (n = 70) used for 138 
further analysis.  139 
For this data set a series of rules was defined in order to classify compounds as having a high or low 140 
DA. For this purpose a preliminary investigation was done using a Decision Tree Builder (KNIME 141 
version 2.10), employing log P, MW, TPSA and MP to determine which descriptors performed better 142 
in classifying compounds as high or low DA (data not shown here). Although the results from the 143 
decision tree alone were not conclusive, they provided guidance on the key descriptors, and 144 
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appropriate cut-off values that could be used to distinguish between high and low DA compounds. 145 
Based on these preliminary investigations, compounds were initially split into classes of low DA 146 
(<1.3%) or high DA (≥1.3%). The value of 1.3% was empirically derived to enable clear distinction 147 
between the classes. Because of the skew in % DA values (i.e. the majority of compounds have a low 148 
DA) the log10 of the DA values was used for ease of visualisation. Compounds showing greater DA 149 
have greater potential to induce systemic toxicity and therefore chemical features associated with 150 
higher percentage of DA are referred to here as physicochemical “alerts”. The performance of the 151 
rules for the data set was investigated by calculating the sensitivity (correct classification of 152 
compounds with high DA) and specificity (correct classification of compounds with low DA). Rigid and 153 
flexible implementation of the derived rules was applied to optimise sensitivity and specificity of the 154 
results. 155 
 156 
  157 
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Results 158 
The following physicochemical alerts, derived from preliminary investigation, were applied: (i) MW < 159 
180 Da, (ii) log P ≥ 0.3, (iii) MP < 100°C, (iv)TPSA < 40 Å2. 160 
Compounds with MW < 180 Da and/or log P ≥ 0.3 and/or MP < 100oC and/or TPSA <40 Å2 are more 161 
likely to be dermally absorbed. TPSA correlates with hydrogen bonding ability and preliminary 162 
investigations indicated that TPSA performed better than counts of hydrogen bond donors/acceptors 163 
in modelling the data here. The results are illustrated in figure 1, which shows that, in general, as the 164 
number of alerts increases the DA increases.  165 
 166 
Figure 1: Boxplot of log10 % DA versus number of alerts for the data set (n=70). The alerts applied here are: MW 167 
<180 Da, log P ≥ 0.3, MP <100°C and TPSA < 40 Å2. (MW= molecular weight, log P = octanol:water partition 168 
coefficient, MP = melting point, TPSA = topological polar surface area, * = outlier), horizontal bars indicate the 169 
median. 170 
 171 
These rules can be interpreted as follows: 172 
If any of the following criteria applies: (i) MW < 180 Da, (ii) log P ≥ 0.3, (iii) MP < 100°C and/or (iv) 173 
TPSA < 40 Å2, then the compound is predicted as highly absorbed. If none of the criteria applies, the 174 
compound is predicted as poorly absorbed. Table 1 summarises the results of applying this rule set to 175 
the data set (n=70). 176 
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Table 1: Performance of the rule set on the data set (n=70). The number of compounds in each category is 177 
given, with the percentage of the total data set between brackets.    178 
n = 70 Predicted High Absorption Predicted Low Absorption Total 
High Absorption (≥1.3%) 23 (32.9%) 0 (0%) 23 (32.9%) 
Low Absorption (<1.3%) 38 (54.3%) 9 (12.9%) 47 (67.1%) 
Total 61 (87.1%) 9 (12.9%)  70 (100%) 
 179 
The rule set shows a high sensitivity of 100% for the data set (i.e. for all 23 compounds in the high DA 180 
class all 23 were correctly predicted as being highly absorbed). The specificity of the rules is low as 38 181 
out of 47 low DA compounds were incorrectly classified as highly absorbed rendering a specificity of 182 
19.1%.  183 
The results show that for the compounds studied here, when the rules predict a compound as having 184 
a low DA then the compound is likely to be poorly absorbed (no false negatives were identified using 185 
these rules). However, when the rules predict a compound as having a high absorption, then the 186 
compound may in fact have either a high or a low DA. 187 
 188 
Flexible analysis of the data set 189 
The same rule set was again applied to the same data set, however in this case additional flexibility 190 
was introduced. When a compound triggered none or only 1 of the alerts then it would still be 191 
predicted as low DA. Only compounds triggering two or more alerts would be assigned to the high 192 
absorption class. Table 2 shows the results for the data using the rule set with this more flexible 193 
interpretation. 194 
 195 
 196 
 197 
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Table 2: Performance of the rule set on the data set (n=70) with flexible interpretation (i.e. compounds must 198 
trigger two alerts to be placed in the high absorption class). The number of compounds in each category is 199 
given, with the percentage of the total data set between brackets.  200 
n = 70 Predicted High Absorption Predicted Low Absorption total 
High Absorption (≥1.3%) 19 (27.1%) 4 (5.7%) 23 (32.9%) 
Low Absorption (<1.3%) 18 (25.7%) 29 (41.4%) 47 (67.1%) 
total 37 (52.9%) 33 (47.1%) 70 (100%) 
 201 
Table 2 shows that application of the rule set with flexible interpretation (i.e. two or more alerts 202 
need to be triggered to classify the compound as high DA) leads to an increased specificity (61.7%), 203 
but to a decreased sensitivity of 82.6% (i.e. 4 high DA compounds are now predicted as low DA). The 204 
increase in specificity may be out-weighed by the loss of sensitivity, as greater “cost” is associated 205 
with a false negative (i.e. predicting a high absorption compound as low DA). 206 
 207 
However, it was noted that the 4 compounds that had been incorrectly classified into the low DA 208 
class all had a DA of < 2%. For this reason the analysis of the data set was repeated but in this case 209 
new boundaries were set for the two classes i.e. compounds for which DA was ≥ 2% were classified 210 
as high DA compounds, whereas those with DA <2% were taken as low DA compounds.  211 
 212 
Results with new boundary criteria  213 
The same rule set was applied to the data set, but with the cut-off value between high and low DA 214 
being set at 2%. Tables 3 and 4 show the results of applying the new cut-off value. In table 3 a 215 
compound is considered to belong to the class of high DA compounds if one or more alerts are 216 
triggered. In Table 4 the rule set is applied more flexibly and a compound is considered to belong to 217 
the high DA class only if two or more alerts are triggered.  218 
 219 
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Table 3: Performance of the rule set on the data set (n=70); triggering one or more alerts indicates a high DA 220 
compound. The number of compounds in each category is given, with the percentage of the total data set 221 
between brackets.   222 
n=70 Predicted High Absorption Predicted Low Absorption Total 
High Absorption (≥2%) 13 (18.6%) 0 (0%) 13 (18.6%) 
Low Absorption (<2%) 48 (68.6%) 9 (12.9%) 57 (81.4%) 
Total 61 (87.1%) 9 (12.9%) 70 (100%) 
 223 
Table 4: Performance of the more flexible rule set on the data set (n=70); triggering two or more alerts 224 
indicates a high DA compound. The number of compounds in each category is given, with the percentage of the 225 
total data set between brackets.   226 
n=70 Predicted High Absorption Predicted Low Absorption Total 
High Absorption (≥2%) 13 (18.6%) 0 (0%) 13 (18.6%) 
Low Absorption (<2%) 24 (34.3%) 33 (47.1%) 57 (81.4%) 
Total 37 (52.9%) 33 (47.1%) 70 (100%) 
 227 
The results given in tables 3 and 4 show that, when a cut-off value for DA of 2% is used, the 228 
sensitivity of the prediction is 100% in both cases. Indeed, compounds of high DA are always 229 
classified as highly absorbed; there are no false negatives. Allowing for a more flexible interpretation 230 
of the rule set, i.e. that 2 or more alerts need to be triggered in order for the compound to be 231 
predicted as having a high DA, increases the specificity – fewer true low DA compounds are predicted 232 
as having a high DA. 233 
 234 
In summary, using the rule set with a cut-off value of 2% will lead to high DA compounds always 235 
being predicted as high (for this data set). However compounds with true low DA may be predicted 236 
as either high or low. More of the true low DA compounds are correctly classified when the more 237 
flexible rules are applied (specificity has increased from 15.8% to 57.9%).  238 
 239 
 240 
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Discussion 241 
For the vast majority of cosmetic products the dermal route is the main route of human exposure. 242 
Therefore DA is a crucial factor in assessing the systemic toxicity of cosmetic ingredients. Another 243 
determining factor is the NO(A)EL. This value is in most cases derived from long-term in vivo 244 
repeated dose toxicity studies. Both factors are incorporated in the calculation of the MoS, an 245 
uncertainty factor to extrapolate from animals to humans (SCCS/1564/15). However, if evidence 246 
suggests that the compound under investigation has a low dermal bioavailability and thus systemic 247 
exposure is minimal, one might consider omitting the assessment of systemic toxicity. In the light of 248 
the animal testing and marketing bans of the European Cosmetic Regulation this would imply that 249 
data derived from an in vivo repeated dose toxicity study, for which no in vitro alternative yet exists, 250 
might not be needed for compounds with a negligible dermal bioavailability. In this context, it is 251 
important to define when a compound is considered to have a negligible dermal bioavailability. As 252 
described in the introduction, it is generally acknowledged that certain physicochemical properties 253 
such as MW, MP, TPSA and log P of a chemical may play an important role in oral and/or dermal 254 
uptake (Potts and Guy 1992, Pugh et al. 2000, Lipinski et al. 2001, Magnusson et al. 2004).  255 
By linking the DA values from the publically available SCCS opinions to the physicochemical 256 
properties MW, MP, TPSA and log P, we have shown that rules can be extracted to identify 257 
compounds suspected to have a low DA and which may be associated with a low dermal 258 
bioavailability.  259 
According to this study the rule set showed a sensitivity of 100% and a specificity of 20%. After 260 
setting new boundary criteria and applying more flexible rules the performance of the rule set was 261 
optimised. The sensitivity of the predictions remained 100%, implying that compounds with a high 262 
DA are always predicted as such and the specificity was increased to 58%, without compromising the 263 
sensitivity. It is indeed preferable not to identify compounds with a high DA as having a low DA. So in 264 
case a compound triggers none or only one of the following alerts: MW < 180 Da, log P ≥ 0.3, MP < 265 
100°C or TPSA < 40 Å2, it is likely to have a low DA and thus a low  dermal bioavailability. The 266 
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presented rule set offered the best consensus between specificity and sensitivity. Adding more 267 
criteria to classify a compound as high dermal absorption, did not lead to a better prediction.   268 
It should be noted that this study comprises a limited set of compounds. Furthermore, several 269 
difficulties were encountered in modelling these DA data. The data have been collated from the 270 
results of different assays using inconsistent methodologies in terms of species, exposure times, 271 
concentrations, matrices, detection methods etc.  Also, it must be noted that the data set analysed 272 
here is skewed very much towards low DA values and that the same rules may not apply when 273 
investigating compounds from different chemical domains. Also, the possibility of bioaccumulation is 274 
not taken into account in this study. Nonetheless, this pragmatic approach shows that when 275 
physicochemical evidence suggests that a cosmetic ingredient has a low DA and thus low dermal 276 
bioavailability, it might be worthwhile to further investigate this by performing more extensive in 277 
vitro DA studies to get more reliable mean values and to confirm the very low DA (i.e. testing 278 
different concentrations, using relevant excipients, increased sample size…). Although the data are 279 
skewed towards low DA, in many cases the DA value used in the SCCS safety dossiers is still over-280 
estimated and more extensive in vitro DA studies might enforce the reliability of the obtained results. 281 
Especially when taking into account that two standard deviations are added to the mean DA value 282 
when the variability between the different measurements is high or when the DA studies have not 283 
been carried out under ideal test conditions. 284 
  285 
To add further to the weight of evidence, existing computational tools could be used to predict oral 286 
bioavailability (Moda et al. 2007; Kumar et al. 2011). In case oral and dermal bioavailability are both 287 
low, it would strengthen the safety assessor’s reasoning to omit the need to calculate the MoS, 288 
making at least for this type of ingredients in vivo repeated dose toxicity studies redundant and to 289 
focus on local toxicity (skin sensitisation and irritation) and mutagenicity/genotoxicity test results. 290 
Since most of the existing computational tools have been developed for pharmaceuticals, evidence 291 
should be provided for their applicability in the cosmetic sector. 292 
14 
 
 293 
To notice for the future is the possibility that when substantial evidence of low bioavailability is 294 
provided, the internal threshold of toxicological concern (TTC) concept might be applied. This 295 
probabilistic approach is used to identify human exposure thresholds below which the risk of 296 
toxicological concern is low by taking into account oral/dermal absorption of the compound (internal 297 
exposure) rather than external exposure (Partosch et al. 2015). For completeness, decisions relating 298 
to internal exposure following oral/dermal administration should include considerations of 299 
metabolism when one wants to omit the determination of the NOA(E)L, since it will then be 300 
important to consider the possibility of metabolic activation. Several in vitro and in silico models are 301 
available for predicting metabolism following oral exposure and there is increasing interest in the 302 
area of skin metabolism for which models are currently being developed (as reviewed recently by 303 
Dumont et al 2015). Though in the cosmetic sector the TTC concept has been accepted for the safety 304 
assessment of impurities for which the identity is known but toxicity data are lacking (Kroes et al. 305 
2007; SCCS/1564/15), more evidence is still needed to prove the applicability of the internal TTC for 306 
cosmetic ingredients. 307 
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